Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Ablynx has scored a major hit in phase 3 trials of caplacizumab, a new treatment for a rare blood clotting disorder. Shares in the Belgian biotech have soared on the news, rising 30% this morning ...